JP6901400B2 - ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 - Google Patents

ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 Download PDF

Info

Publication number
JP6901400B2
JP6901400B2 JP2017552082A JP2017552082A JP6901400B2 JP 6901400 B2 JP6901400 B2 JP 6901400B2 JP 2017552082 A JP2017552082 A JP 2017552082A JP 2017552082 A JP2017552082 A JP 2017552082A JP 6901400 B2 JP6901400 B2 JP 6901400B2
Authority
JP
Japan
Prior art keywords
cancer
amino acid
seq
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017552082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518454A5 (OSRAM
JP2018518454A (ja
Inventor
アメール エム． ミルザ
アメール エム． ミルザ
ローズマリー ジェイ． アクハースト
ローズマリー ジェイ． アクハースト
オウ リ
オウ リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2018518454A publication Critical patent/JP2018518454A/ja
Publication of JP2018518454A5 publication Critical patent/JP2018518454A5/ja
Priority to JP2021100601A priority Critical patent/JP7242760B2/ja
Application granted granted Critical
Publication of JP6901400B2 publication Critical patent/JP6901400B2/ja
Priority to JP2023035685A priority patent/JP2023063377A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017552082A 2015-04-03 2016-04-03 ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 Expired - Fee Related JP6901400B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021100601A JP7242760B2 (ja) 2015-04-03 2021-06-17 ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法
JP2023035685A JP2023063377A (ja) 2015-04-03 2023-03-08 ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562143016P 2015-04-03 2015-04-03
US62/143,016 2015-04-03
US201562191797P 2015-07-13 2015-07-13
US62/191,797 2015-07-13
PCT/US2016/025802 WO2016161410A2 (en) 2015-04-03 2016-04-03 Treatment of cancer using inhibitors of tgf-beta and pd-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021100601A Division JP7242760B2 (ja) 2015-04-03 2021-06-17 ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法

Publications (3)

Publication Number Publication Date
JP2018518454A JP2018518454A (ja) 2018-07-12
JP2018518454A5 JP2018518454A5 (OSRAM) 2019-05-16
JP6901400B2 true JP6901400B2 (ja) 2021-07-14

Family

ID=56920908

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552082A Expired - Fee Related JP6901400B2 (ja) 2015-04-03 2016-04-03 ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
JP2021100601A Active JP7242760B2 (ja) 2015-04-03 2021-06-17 ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法
JP2023035685A Pending JP2023063377A (ja) 2015-04-03 2023-03-08 ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021100601A Active JP7242760B2 (ja) 2015-04-03 2021-06-17 ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法
JP2023035685A Pending JP2023063377A (ja) 2015-04-03 2023-03-08 ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法

Country Status (6)

Country Link
US (4) US10167334B2 (OSRAM)
EP (2) EP3277716B1 (OSRAM)
JP (3) JP6901400B2 (OSRAM)
CN (2) CN116327915A (OSRAM)
ES (1) ES2820768T3 (OSRAM)
WO (1) WO2016161410A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021155431A (ja) * 2015-04-03 2021-10-07 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CA2997240C (en) * 2015-09-03 2024-04-02 Ono Pharmaceutical Co., Ltd. Immunity enhancing agent for cancer by allergin-1 antagonist
ES2911038T3 (es) 2016-03-15 2022-05-17 Inst Nat Sante Rech Med Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad
EP3565599A4 (en) * 2017-01-07 2020-07-01 Merck Patent GmbH DOSAGE PATTERNS AND DOSAGE FORMS FOR TARGETED INHIBITION OF TGF-B
TWI787230B (zh) * 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
EA201991729A1 (ru) * 2017-01-20 2019-12-30 Санофи Антитела к tgf-бета и их применение
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US12060577B2 (en) 2017-05-19 2024-08-13 Case Western Reserve University Compositions for expanding natural killer cells
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en) * 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN111821434A (zh) * 2019-04-17 2020-10-27 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗实体瘤的药物中的用途
KR20210006405A (ko) * 2018-05-04 2021-01-18 메르크 파텐트 게엠베하 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
US11377488B2 (en) * 2018-07-03 2022-07-05 Catalent Pharma Solutions, Llc Multifunctional protein molecules comprising decorin and use thereof
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
US20210340240A1 (en) * 2018-10-18 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US20210396737A1 (en) * 2018-11-21 2021-12-23 Highlight Therapeutics, S.L. Nanoplexed poly(i:c) formulations and uses thereof
WO2020146345A1 (en) * 2019-01-07 2020-07-16 Children's Medical Center Corporation Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy
PH12021551860A1 (en) 2019-01-30 2022-05-16 Scholar Rock Inc Ltbp complex-specific inhibitors of tgf㟠and uses thereof
CN113557236B (zh) * 2019-06-10 2022-05-10 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CN110464841B (zh) * 2019-08-19 2020-05-22 启辰生生物科技(珠海)有限公司 免疫增强的药物组合物及其应用
CN110734498A (zh) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
EP4048704A4 (en) * 2019-10-21 2023-11-22 Nanjing Leads Biolabs Co., Ltd. RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß
CA3154413A1 (en) * 2019-11-01 2021-05-06 Yan Lan Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer
KR20220116257A (ko) * 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
CN115175942B (zh) * 2020-02-25 2025-05-30 上海药明生物技术有限公司 一种双功能融合蛋白及其用途
KR20230003178A (ko) * 2020-04-29 2023-01-05 치아타이 티안큉 파마수티컬 그룹 주식회사 PD-1 및 TGF-β에 대한 이중 기능성 단백질
JP7419168B2 (ja) * 2020-06-10 2024-01-22 株式会社東芝 改変型ｐｉｇｇｙＢａｃトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304979A (zh) * 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN116547300B (zh) * 2021-09-30 2024-10-08 贝达药业股份有限公司 双特异性抗体及其应用
KR102763607B1 (ko) * 2021-10-05 2025-02-07 주식회사 인게니움테라퓨틱스 자연살해 세포의 활성 향상용 조성물
CN116327956B (zh) * 2022-04-01 2025-11-28 劲方医药科技(上海)股份有限公司 药物组合物、其用途及癌症的治疗方法
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
AU689755B2 (en) 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
US7369111B2 (en) 2003-04-29 2008-05-06 Samsung Electronics Co., Ltd. Gate driving circuit and display apparatus having the same
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP1796715A2 (en) 2004-09-22 2007-06-20 Genzyme Corporation USE OF TGF-ß ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ES2379194T3 (es) 2005-12-23 2012-04-23 Eli Lilly And Company Anticuerpos de unión a TGF-beta
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
US9518112B2 (en) * 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3105246B1 (en) * 2014-02-10 2021-03-31 Merck Patent GmbH Targeted tgf beta inhibition
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021155431A (ja) * 2015-04-03 2021-10-07 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
JP7242760B2 (ja) 2015-04-03 2023-03-20 ゾーマ テクノロジー リミテッド ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法

Also Published As

Publication number Publication date
JP7242760B2 (ja) 2023-03-20
US10683347B2 (en) 2020-06-16
WO2016161410A3 (en) 2016-11-10
JP2021155431A (ja) 2021-10-07
HK1253276A1 (zh) 2019-06-14
CN108136001B (zh) 2022-07-29
US20190112366A1 (en) 2019-04-18
US20160289315A1 (en) 2016-10-06
CN116327915A (zh) 2023-06-27
ES2820768T3 (es) 2021-04-22
EP3277716A2 (en) 2018-02-07
CN108136001A (zh) 2018-06-08
US11685775B2 (en) 2023-06-27
EP3277716B1 (en) 2020-06-24
US20230416354A1 (en) 2023-12-28
WO2016161410A2 (en) 2016-10-06
EP3770171A1 (en) 2021-01-27
US20200308266A1 (en) 2020-10-01
US10167334B2 (en) 2019-01-01
JP2023063377A (ja) 2023-05-09
JP2018518454A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
JP7242760B2 (ja) ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法
JP6877500B2 (ja) ＴＧＦ−βに特異的な抗体
US12234285B2 (en) Antibodies that bind interleukin-2 and uses thereof
CN111499747A (zh) 一种抗cd73单克隆抗体及其应用
JP2020536109A (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
CN107074950A (zh) 使用抗nkg2a抗体的治疗方案
JP2020537520A (ja) Ｃｄ１３７を標的とする抗体とその利用方法
JP2018511311A (ja) 造血器腫瘍およびリンパ腫におけるｃｄ９９を標的とする組成物および方法
JP2019526244A (ja) 副甲状腺ホルモン受容体１（ｐｔｈ１ｒ）抗体およびその使用
HK40044715A (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
HK1253276B (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
HK40064966A (en) Antibodies specific for tgf-beta
HK1196830B (en) Antibodies specific for tgf-beta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210617

R150 Certificate of patent or registration of utility model

Ref document number: 6901400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees